The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Shuanggang Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Yuebei People's Hospital, Shantou University Medical College, Shaoguan 512025, Guangdong, People's Republic of China; Departm…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a highly heterogeneous disease. Thermal ablation has the advantages of being equivalent to surgical resection, minimally invasive, low cost and significantly reducing hospital stay. Therefore, it is recommended as one of the first-line radical treatment for early HCC. However, with the deepening of research on early HCC, more and more studies have found that not all patients with early HCC can obtain similar efficacy after radical thermal ablation, which may be related to the heterogeneity of HCC. Previous studies have shown that inflammation and immunity play an extremely important role in the prognostic heterogeneity of patients with HCC. Therefore, the inflammatory response and immune status of patients may be closely related to the efficacy of early HCC after curative thermal ablation. This article elaborates the mechanism of high inflammatory response and poor immune status in the poor prognosis after radical thermal ablation of early HCC, and clarifies the population who may benefit from adjuvant therapy after radical thermal ablation in patients with early HCC, which provides a new idea for the precise adjuvant treatment after radical ablation of early HCC in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Yuebei People's Hospital, Shantou University Medical College, Shaoguan 512025, Guangdong, People's Republic of China; Department of Minimally Invasive Interventional Therapy, Sun Yat-sen Universi…
- Department of Nursing, Medical College of Shaoguan University, Shaoguan 512026, People's Republic of China.
- Department of Interventional Therapy, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China.
- Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, People's Republic of China; State Key Laboratory of Oncology in South China, Collaborative Innovation Cent…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, S., Shen, B., Wu, Y., Shen, L., Qi, H., Cao, F., Huang, T., Tan, H., Wen, C., & Fan, W. (2023). The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110228
Vancouver
Chen S, Shen B, Wu Y, Shen L, Qi H, Cao F, et al. The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110228
BibTeX
@article{Chen2023,
author = {Chen, Shuanggang and Shen, Binyan and Wu, Ying and Shen, Lujun and Qi, Han and Cao, Fei and Huang, Tao and Tan, Hongtong and Wen, Chunyong and Fan, Weijun},
title = {The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110228}
}
EUVIMED